Several lines of evidence indicate that BRCA-mutated patients had lower levels of AMH when compared to non-BRCA populations [17,18,24,31,32,33], and a recent meta-analysis confirmed this data [34] with an AMH that was 1.0 ng/mL lower in BRCA-mutated patients before FP for BC compared to non-carriers with BC. The gene discussed is AMH; the disease is breast cancer.